# Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

> **NCT05113355** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 23 (estimated)

## Conditions studied

- Neuroendocrine Tumors
- Neuroendocrine Tumor Grade 3
- Neuroendocrine Carcinoma
- Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT05113355
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-17
- **Primary completion:** 2022-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113355, "Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05113355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*